CA
NZ
UK
AU
IND
US
Quest Diagnostics announced an upward revision to its earnings‑per‑share outlook for 2026 after posting a second‑quarter performance that outstripped market expectations. The guidance lift comes at a time when investors are scrutinizing profit growth across the health‑care testing sector, and the company’s improved outlook …
Solstice Health's commitment to redefined healthcare has earned it recognition as a 2026 Future 50 company, with patient numbers surging by over 140%. This growth underscores a shift towards direct care models, appealing to investors seeking opportunities in evolving healthcare systems.Key HighlightsSolstice Health’s patient …
Summit Therapeutics Inc. (NASDAQ: SMMT) disclosed that its cash and investment holdings total $690.7 million at the close of the most recent quarter. This liquidity provides a solid foundation for the company’s ongoing oncology initiatives, including the development of its lead candidate, ivonescimab, which …
Codexis, Inc. anticipates revenue reaching at least $14.8 million for the second quarter of 2026. This increase reflects the company’s operational growth, impacting its market positioning and investor outlook positively.Key HighlightsCodexis, Inc. forecasts at least $14.8 million in revenue for the quarter ending June …
Proposed tariffs on generic drugs could double prices in the U.S., according to the CEO of Dr. Reddy's. This significant increase will burden countless American patients, prompting calls for Big Pharma to reshore drug production within two years to avoid the financial impact.Key HighlightsDr. …
Edwards Lifesciences Corp reported Q2 sales of $1.74 billion, up 13.6%, leading to a raised sales guidance for 2026. This solid growth underscores the company's strength in structural heart therapies, though shares are down year-to-date.Key HighlightsQ2 sales surged 13.6% to $1.74 billion, demonstrating strong …
Faeth Therapeutics, Inc. This is an impressive move indicating strong internal confidence, particularly as the company’s market capitalization stands at approximately $731 million. The recent developments come as the stock has soared over 187.8% year-to-date, highlighting a potent mix of strategic adjustments and market …
Freenome, Inc. has finalized a significant business combination that has resulted in gross proceeds of approximately $310.3 million, bolstering its financial resources significantly. This strategic move comes at a key time as the company seeks to enhance its capabilities in genomic testing solutions for …
Healthy Extracts Inc. (OTC: HYEX) secured $225,000 cash by issuing a $258,750 promissory note, convertible at $2.00 per share or 75% of recent low price. The infusion eases liquidity amid a 66% one‑month stock decline, but conversion could further dilute shareholders.Key HighlightsPromissory note principal …
MacroGenics has reported encouraging interim results for MGC026, a novel cancer treatment, with shares showing a 149.1% increase year-to-date. Investors are optimistic as the company prepares to present data at ESMO 2026, highlighting its potential in advancing cancer therapies.Key HighlightsMacroGenics’ shares are up 149.1% …
Please wait processing your request...